NSE: DRREDDY | BSE: 500124

Mid-range Performer

Download real time

1219.50 8.10 (0.67%)

1.3M NSE+BSE Volume

NSE 11 Aug, 2025 3:56 PM (IST)

101,777.3

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Dr. Reddy's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DRREDDY, BSE:500124 Dr. Reddy's Laboratories Ltd.

Search Inside the pdf :

Dr. Reddy's Laboratories Ltd.

29 Jul 2025

1219.50

0.67%

Price Erosion across the US portfolio to remain the key overhang for its overall business

Sell: Dr. Reddy's Laboratories Ltd.

Deven Choksey

Revenue: For Q1FY26, the revenue increased by 11.4% YoY (+0.5% QoQ) to INR 85,721 Mn, below our estimates by 3.0%, led by weakness in North America, which was partially offset by higher momentum across Europe and the Emerging markets.

Dr. Reddy's Laboratories Ltd. is trading below all available SMAs

Dr. Reddy's Laboratories Ltd.

24 Jul 2025

1219.50

0.67%

Dr. Reddy's Laboratories (DRRD IN) Q1FY26 Result Update ...

Sell: Dr. Reddy's Laboratories Ltd.

Target

Prabhudas Lilladhar

Dr. Reddy's (DRRD) Q1FY26 EBITDA adjusted for licensing income was in line with our estimate. The base business margins and US sales ex of gRevlimid continued to remain weak. We have scale up base business margins from the current level of 15-16% to +21-22% in FY27E. Our FY26 and FY27E EPS broadly remain unchanged. DRRD have been investing cash flow from gRevlimid to build pipeline across peptides, biosimilars and GLP products; benefits of that may take some time. Further thin US pipeline in near term and competition in...

Number of FII/FPI investors increased from 911 to 917 in Jun 2025 qtr.

Dr. Reddy's Laboratories Ltd.

24 Jul 2025

1219.50

0.67%

Result Update:Dr Reddys Labs

Hold: Dr. Reddy's Laboratories Ltd.

Recommendation Target

Axis Direct

We maintain our HOLD recommendation on with a target price of Rs 1,360/share, implying an upside potential of 9% from the CMP.

Dr. Reddy's Laboratories Ltd. is trading below all available SMAs

Dr. Reddy's Laboratories Ltd.

23 Jul 2025

1219.50

0.67%

Out-licensing income/lower R&D spend drive better-thanexpected EBITDA

Neutral: Dr. Reddy's Laboratories Ltd.

Target

Motilal Oswal

Dr Reddy’s Labs (DRRD) reported sales in line with our estimates in 1QFY26, while EBITDA/PAT came in higher than expected, primarily led by higher outlicensing income and lower R&D expenses.

Number of FII/FPI investors increased from 911 to 917 in Jun 2025 qtr.

Dr. Reddy's Laboratories Ltd.

07 Jul 2025

1219.50

0.67%

DR. REDDY'S LABORATARIES

Sell: Dr. Reddy's Laboratories Ltd.

Geojit BNP Paribas

*over or under performance to benchmark index Dr. Reddy's Laboratories (Dr. Reddy's) is an Indian pharmaceuticals company that manufactures and markets more than 190 medications, 180+ active pharmaceutical...

Deven Choksey released a Sell report for Dr. Reddy's Laboratories Ltd. with a price target of 1120.0 on 29 Jul, 2025.

Dr. Reddy's Laboratories Ltd.

12 May 2025

1219.50

0.67%

Dr. Reddy's Laboratories (DRRD IN) Q4FY25 Result Update ...

Sell: Dr. Reddy's Laboratories Ltd.

Target

Prabhudas Lilladhar

Dr. Reddy's (DRRD) Q4FY25 EBITDA was below our estimate. The base business margins and US sales ex of gRevlimid continued to remain weak. We have scale up base business margins from current level of 16% to +20% in FY27E. Our FY27E EPS stands cut by 4-5%. DRRD have been investing cash flow from gRevlimid to build pipeline across peptides, biosimilars and GLP products; benefits of that may take some time. Further thin US pipeline in near term and...

Dr. Reddy's Laboratories Ltd. is trading below all available SMAs

Dr. Reddy's Laboratories Ltd.

24 Jan 2025

1219.50

0.67%

Core US business weakness coming to the fore

Sell: Dr. Reddy's Laboratories Ltd.

Target

Emkay

Adjusted for the milestone payment received from Journey Medical Corp, 3QFY25 EBITDA for Dr Reddy’s was below street/our estimates. The PAT miss was higher on account of lower other income.

Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

24 Jan 2025

1219.50

0.67%

Soft g-Revlimid sales, high expenses dent earnings

Neutral: Dr. Reddy's Laboratories Ltd.

Target

Motilal Oswal

DRRD delivered in-line sales (adj. for NRT acquisition and milestone income) and marginally better operational performance in 3QFy25. Revenue/EBITDA YoY growth was moderate due to lower off-take of g-Revlimid and PSAI business, which was offset to some extent by healthy performance in the Russia market